Cervical adenosarcoma

Summary

Cervical adenosarcoma (MONDO:0002876) is a disease and 2 clinical trials. Top therapeutic interventions include bevacizumab. A subtype of adenosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
• Clinical trials: 2

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000		Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	cervical adenosarcoma
Mondo ID	MONDO:0002876
Orphanet	213792
DOID	DOID:4111
NCIT	C40229
SNOMED CT	764847000
UMLS	C1516426
MedGen	308948
GARD	0020492
Anatomy (UBERON)	UBERON:0000002
Is cancer (heuristic)	no

Also known as: adenosarcoma of the cervix uteri · adenosarcoma of uterine cervix · cervical adenosarcoma · cervical Mullerian adenosarcoma · cervical Müllerian adenosarcoma · uterine cervix adenosarcoma

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › adenosarcoma › cervical adenosarcoma

Related subtypes (4): fallopian tube adenosarcoma, uterine corpus adenosarcoma, ovarian adenosarcoma, vaginal adenosarcoma

Subtypes (1): uterine ligament adenosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02020707	PHASE1	COMPLETED	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
NCT07394413	Not specified	NOT_YET_RECRUITING	Surgical Handling of Fertility-preserving Treatments for Cervical Adenocarcinomas

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	1